A 28-week clinical trial in patients with primary hypercholesterolemia or mixed hyperlipidemia to study the effects of MK0524A on lipids and tolerability. There will be 9 scheduled clinic visits, and 3 treatment groups. A patient can be randomly assigned to 1 of the 3 treatment groups.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
1,620
Duration of Treatment - 24 weeks
Duration of Treatment - 24 weeks
Reductions of LDL-C concentrations at 24 weeks and better tolerability
Time frame: at 24 weeks
Elevations in HDL-C concentrations at 24 weeks
Time frame: at 24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.